Vasodilator‐stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events

Background: Despite dual antiplatelet therapy, the rate of major adverse cardiovascular events (MACE) after percutaneous coronary angioplasty remains high. Studies have shown interindividual variations in response to clopidogrel. Furthermore, there is an apparent link between clinical outcomes and c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thrombosis and haemostasis 2007-08, Vol.5 (8), p.1630-1636
Hauptverfasser:	BONELLO, L., PAGANELLI, F., ARPIN‐BORNET, M., AUQUIER, P., SAMPOL, J., DIGNAT‐GEORGE, F., BARRAGAN, P., CAMOIN‐JAU, L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Angioplasty, Balloon, Coronary - methods biological resistance to clopidogrel Blood Platelets - metabolism Cardiovascular Diseases - prevention & control Cardiovascular Diseases - therapy Cell Adhesion Molecules - biosynthesis Cell Adhesion Molecules - chemistry coronary angioplasty Female Humans major adverse cardiovascular events Male Microfilament Proteins - biosynthesis Microfilament Proteins - chemistry Middle Aged Phosphoproteins - biosynthesis Phosphoproteins - chemistry Phosphorylation Platelet Aggregation Inhibitors - pharmacology platelet reactivity Predictive Value of Tests Prospective Studies Ticlopidine - analogs & derivatives Ticlopidine - pharmacology Vasodilator Agents - pharmacology vasodilator‐stimulated phosphoprotein phosphorylation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!